NASDAQ
Evolutionary Genomics, Inc. (FNAM) has a free cash flow growth of -42.54% as of Friday, May 29, 2026. This represents a 223.43% decrease compared to its 12-month average of 34.47%. Free cash flow growth tracks the year-over-year percentage change in cash generated after capital expenditures.
No price data available for this timeframe.